Urica Therapeutics, Inc. (Urica) is a majority-owned subsidiary of Fortress Biotech, Inc. (Nasdaq: FBIO) and originally licensed dotinurad, a novel urate transporter (URAT1) inhibitor from Fuji Yakuhin Co. Ltd. in 2021.
In July 2024, Urica entered into an asset purchase agreement, royalty agreement, and related agreements with Crystalys Therapeutics, Inc. (Crystalys) whereby Urica transferred rights to dotinurad and related intellectual property, license and agreements to Crystalys. For more information, please click here.
Scroll to top
